Main remarks from Cytokinetics Inc. (Nasdaq: CYTK) last PRs and quarterly results are:
- Data from the phase II trial of ‘357 in myasthenia gravis are delayed until 1H of 2012.
- Amgen (Nasdaq: AMGN) is continuing the development of Omecamtiv mercabil (OM) in its phase IIb safety and efficacy trial, now dubbed ATOMIC-AHF. Remember that top-line data won’t be released until 1H 2013.
- Cytokinetics is collecting data from a Part A study of its phase II PK, PD, multiple dose, safety and tolerability trial of ‘357 in patients with ALS who are not getting riluzole. Data will be presented at the 22nd International Symposium on ALS and Motor Neurone Diseases Meeting in Sydney, Australia on November 30 – December 2. It initiated a Part B in patients who are also receiving riluzole on Nov 1 with results expected in 1H of 2012